Showing results (111-120 of 453) with videos related to

Sort By:
Pageof 46
NPJ Precision Oncology|January 11, 2023
Antibody-drug conjugates in lung cancer: dawn of a new era?Niamh Coleman, Timothy A Yap, John V Heymach, et al.
CA: a Cancer Journal for Clinicians|January 6, 2011
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicTimothy A Yap, Shahneen K Sandhu, Craig P Carden, et al.
Cancer Discovery|November 3, 2025
Germline Mutations as Cancer Drug TargetsTin-Yun Tang, Karen Colbert Maresso, Joanne Ngeow, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2016
Development of molecularly targeted agents and immunotherapies in small cell lung cancerAdam Sharp, Jaishree Bhosle, Fatma Abdelraouf, et al.
Drugs|April 6, 2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung CancerSaoirse O Dolly, Dearbhaile C Collins, Raghav Sundar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Circulating tumor cells: a multifunctional biomarkerTimothy A Yap, David Lorente, Aurelius Omlin, et al.
Investigational New Drugs|September 11, 2020
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancerAnalía Azaro, Capucine Baldini, Jordi Rodon, et al.
Cancer Research Communications|August 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase 1 UnitCamila Braganca Xavier, Clark R Andersen, JoAnn Lim, et al.
Oncoscience|January 17, 2015
A framework for genomic biomarker actionability and its use in clinical decision makingSmruti J Vidwans, Michelle L Turski, Filip Janku, et al.
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
Pageof 46